Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit.
Auteurs : Sabbah M, Krayem M, Najem A, Sales F, Miller W, Del Rincon S, Awada A, Ghanem GE, Journe F
Jaar : 2021
Journal : Mol Cancer Res